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Background: Multiple sclerosis (MS) is the most common cause of neurological disability in young adults
worldwide and approximately half of those affected are in Europe. The assessment of differential incidence and
prevalence across populations can reveal spatial, temporal and demographic patterns which are important for
identifying genetic and environmental factors contributing to MS. However, study methodologies vary and the
quality of the methods can influence the estimates. This study aimed to systematically review European studies
of incidence and prevalence of MS and to provide a quantitative assessment of their methodological quality.
Methods: A comprehensive literature search was performed to obtain all original population-based studies of MS
incidence and prevalence in European populations conducted and published between January 1985 and January
2011. Only peer-reviewed full-text articles published in English or French were included. All abstracts were
screened for eligibility and two trained reviewers abstracted the data and graded the quality of each study using
a tool specifically designed for this study.
Results: There were 123 studies that met the inclusion criteria. The study estimates were highly heterogeneous,
even within regions or countries. Quality was generally higher in the more recent studies, which also tended to
use current diagnostic criteria. Prevalence and incidence estimates tended to be higher in the more recent
studies and were higher in the Nordic countries and in northern regions of the British Isles. With rare exceptions,
prevalence and incidence estimates were higher in women with ratios as high as 3:1. Few studies examined
ethnicity. Epidemiological data at the national level was uncommon and there were marked geographical
disparities in available data, with large areas of Europe unrepresented and other regions well-represented in the
literature. Only 37% of the studies provided standardized estimates.
Conclusions: Despite the breadth of the literature on the epidemiology of MS in Europe, inter-study
comparisons are hampered by the lack of standardization. Further research should focus on regions not yet
studied and the evaluation of ethnic differences in MS prevalence and incidence. National-level studies using
current diagnostic criteria, validated case definitions and similar age- and sex-standardization would allow better
geographical comparisons.
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Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system that typically presents in
the third or fourth decade of life. It is estimated that
more than 2 million people have MS worldwide and the
disease is among the most common causes of neurological
disability in young adults [1]. The distribution and fre-
quency of MS are assessed by estimates of prevalence and
incidence. These measures provide essential information
for health service planning, and can be used to monitor or
reveal spatial, temporal and demographic differences in
the distribution of disease. Comparisons of incidence and
prevalence in different populations support assessments
of the relative contribution of genetic and environmental
factors in MS aetiology [2].
MS is recognized worldwide, however reported incidence
rates (the proportion of new cases during a defined time
period) and prevalence (the proportion of the population
that has the disease at or during a specified time) vary
considerably between regions and populations [1]. The
observed patterns appear consistent with differential
genetic predispositions and also implicate environmental
risk factors that modulate the risk of MS at the population
level [3]. Results of meta-analyses suggest that the inci-
dence of MS has increased over time and provide some
evidence that this has primarily resulted from an increase
in the incidence of MS among women [4-8]. Europe is
considered a high prevalence region for MS (defined by
Kurtzke as a prevalence ≥ 30/100,000 [9]), containing
more than half of the global population of people diag-
nosed with MS [1]. Nevertheless, a great deal of uncer-
tainty remains about how the risk of MS varies among
European populations. The aim of this study was to
systematically review the prevalence and incidence of
MS across Europe. The quality of the published studies
along with the temporal and geographical trends were




This review was part of a larger study on the worldwide
incidence and prevalence of MS, which included all ori-
ginal population-based studies published in English or
French between January 1st 1985 and January 31st 2011.
The start date of 1985 was chosen in part because the
introduction of magnetic resonance imaging (MRI) at
that time substantially influenced the diagnosis of MS
and thus the reliability of case definitions for prevalence
and incidence studies. A comprehensive literature search
was performed as previously described [10]. The search
terms ‘multiple sclerosis’, ‘incidence’, ‘prevalence’ and
‘epidemiology’ were entered in MEDLINE and EMBASE
databases (see Additional file 1 for detailed search strat-egies), and review articles and bibliographies of original
studies so identified were hand searched for potentially
relevant studies. Studies in which all data collection was
carried out earlier than January 1st 1985 and those that
were reported solely as conference presentations or ab-
stracts were excluded.
Two reviewers (RAM, SK or CW) independently screen-
ed the abstracts to assess whether each study met all
eligibility criteria. If eligibility could not be ascertained
by review of the abstract, the full text of the article was
reviewed. All articles that met eligibility criteria by con-
sensus of both reviewers were retained.Data extraction and quality assessment
For each article, one trained reviewer abstracted data onto
a standardized form, including: study location, prevalence
day or period, sources for case ascertainment, diagnostic
criteria and average age of the study population. Crude
and standardized (when available) prevalence and inci-
dence estimates were documented overall and by sex,
region, time period and subgroup as applicable. Extracted
data were verified by a second reviewer.
Two reviewers independently assessed the quality
of each study using a tool designed for this review
(Additional file 2) and based on a scoring system suggested
by Boyle [1]. The questions aimed to evaluate: the validity
of the chosen diagnostic criteria, the representativeness
of the study population, the inclusion of confidence in-
tervals, how well the study population was defined, and
the reliability and completeness of the data. Each study
was scored out of 7 or 8 points based on one potential
affirmative score per question. One question applied
only to studies that used health administrative data
sources; these studies were scored out of 8 while studies
using multiple sources of ascertainment were scored
out of 7. Conflicts were resolved by consensus. Data ab-
straction and quality reviews were conducted using the
web-based DistillerSR program (Evidence Partners, Ottawa,
Canada).
All European studies were then selected to facilitate
detailed examination; Russia was included but Turkey,
Kazakhstan, Azerbaijan and Georgia were not (these
are included in a separate review of studies from Asia;
in preparation). The studies were grouped into eight
regions to allow more descriptive analysis: the Italian
Peninsula and Malta; the British Isles; the Nordic region;
the Iberian Peninsula; Belgium and France; the Central
European countries; South East Europe; and the Baltic states,
including Russia. All data extracted from the European
studies were manually verified by one reviewer (EK).
Where possible, female to male prevalence and incidence
ratios were calculated from reported data whenever sex
ratios were not explicitly reported in the manuscripts.
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lence studies for each European region and for all European
studies combined. Studies that did not report either the
crude estimate with the confidence interval or the number
of cases and the population denominator were excluded
from these calculations. We examined the resulting I2
statistic, which describes the proportion of variation in
point estimates due to heterogeneity between studies
rather than to sampling error; a χ2 test of homogeneity
was conducted to determine the strength of evidence
that heterogeneity was genuine.
Results
The initial global literature search yielded 3,256 citations
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Figure 1 Flow diagram of selection of MS incidence and prevalence sences identified by hand searches (see Figure 1). Thirty-
three European studies were excluded because of language
(eight from Spain, seven from Russia, five from Poland,
three Norwegian, three Ukrainian, two German, one
Danish, one Czech, one Slovakian, one Serbian and one
from the former Yugoslavia). Of the 183 worldwide studies
that met the selection criteria, 123 unique studies were
conducted in Europe; all data extracted from the European
incidence and prevalence studies, with the assessed quality
scores, are presented in Additional file 3: Table S1
and Additional file 4: Table S2 respectively (listed
chronologically by year of publication, within country).
Even when stratified by region, heterogeneity among
studies was found to be high (I2 ≥ 84.4%, p<0.0001)
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Figure 2 Heterogeneity of prevalence estimates from included studies, stratified by region.
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was not performed.
Prevalence estimates were more frequently reported
than incidence estimates; 113 of the 123 studies reportedprevalence estimates while 74 reported incidence estimates.
Across Europe and over time, point prevalence estimates
varied considerably. Estimates as low as ≤ 20/100,000 were
reported in some studies conducted in the 1980s [11-14],
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ethnic minority populations of Norway and Bulgaria
[16,17]. High estimates of ≥ 200/100,000 were reported in
parts of Scotland and Northern Ireland and also within
specific populations in Scandinavia [18,19] and Sicily [20].
Likewise, estimated annual incidence rates ranged widely
from < 1/100,000 [11,15] to > 10/100,000 [20-22].
In the majority of studies the prevalence of MS was
higher in women with sex ratios ranging from 1.1 to 3.
The average female to male prevalence ratio overall was
approximately 2, ranging from 1.6 for South East Europe
to 2.7 for studies from Central Europe; average preva-
lence ratios across Europe ranged between 1.6 to 2.8 in
the 1980s, 1.8 to 2.5 in the 1990s and 1.8 to 2.4 in the
2000s. Exceptions to the excess prevalence of women
were noted in a small district of Northern Sweden (fe-
male to male ratio: 0.76) where several of the identified
cases were related [18], and among Turkish-speaking
communities in Cyprus, (female to male ratio: 0.5) [23].
Relatively low female to male prevalence ratios (between
1 and 1.1) were seen in Greek-speaking communities in
Cyprus [24], in Catania, Sicily (1989) [13] and in African
and Asian ethnic populations in Norway [17]. However,
when available, sex incidence ratios revealed generally
higher rates for women that were in keeping with the
overall higher female sex ratio for prevalence. As inci-
dence ratios are not subject to survivor bias and are more
etiologically relevant, their discussion is emphasized in
favour of prevalence ratios in the description of the re-
gional findings below.
In most of the reviewed studies cases were ascertained
from a variety of sources including hospital and clinic
records, neurologists and other physicians, patient as-
sociations and, in more recent years, from MS registries
or administrative databases. Diagnosis was typically es-
tablished through assessment by a health professional
or review of medical records. MS cases were defined
most frequently using the Poser criteria [25] (79% of
studies), although the inclusion or exclusion of ‘probable’
or ‘possible’ MS cases was not consistent across studies.
The 2001 McDonald [26], Rose [27] and Schumacher [28]
criteria were used in most of the remaining studies while
the McAlpine [29] or McDonald/Halliday [30] criteria
were used rarely.
Study quality scores varied from 1 to the maximum (7 or
8), and were somewhat lower for earlier studies compared
to more recent reports. The mean quality score was 4.31
(standard deviation [SD]: 0.97) for studies conducted
during or ending in the 1980s in contrast to 4.86 (SD:
1.02) for those conducted in the 1990s and 5.35 (SD:
1.08) after 2000. Lower quality scores were due to unclear
reporting of standardized methods (78% of the studies)
or because confidence intervals were not included (25%
of the studies). Only 37% of the studies providedstandardized estimates, although the diversity of stand-
ard populations chosen by the different studies hinders
direct comparisons’ of estimates. Nevertheless, esti-
mates that are standardized to a large standard popula-
tion are preferable to crude estimates and these adjusted
estimates, when available, are presented in the following
descriptive summaries.Italian Peninsula and Malta
Italy has been particularly well-studied, although no single
study evaluated the complete Italian mainland. Among the
28 reviewed studies from this region, nine were conducted
in Sicily [13,20,31-37], seven in Northern Italy [38-44],
seven in Sardinia [45-51], two in Central Italy [52,53], and
one each in the south of Italy [54], San Marino [55] and
Malta [15]. The Poser diagnostic criteria were used to
identify cases in 25/28 of the studies. Prevalence estimates
ranged from a low of 15.8/100,000 to a high of 197.8/
100,000, with the most extreme variation seen between
the studies within Sicily [13,20]. Annual incidence esti-
mates also varied widely across the region, ranging from
0.7 per 100,000 in the Maltese-born population of Malta
[15] to 9.2/100,000 in central Sicily [31]. A particularly
high incidence estimate of 18.2 per 100,000, for the small
town of Linguaglossa, Sicily [20], is thought to represent a
geographical and temporal cluster of cases.
It has been suggested that due to different genetic and
environmental influences, Sardinia has a higher incidence
and prevalence of MS compared to the rest of Italy [56].
Supporting this theory, five of the six studies of the
Sardinian population have estimated the prevalence of
MS at higher than 100/100,000 [45-47,49,51]. The only
study with a lower estimate (69/100,000) was carried out
in 1985 [50]. However, when considering the incidence of
MS, the Sardinian estimates (3.4 to 6.8/100,000) were not
unlike those seen across the entire Italian peninsula.
Female to male ratios for MS incidence tended to be
lower in Sicily; ranging from 1.19:1 to 1.84:1 [20,31-34,36]
but were as high as 3:1 in San Marino [55] and Northwestern
Sardinia [51]. The quality scores ranged between 3/7 and
6/7 with six of the studies from the Italian peninsula scor-
ing 6/7 [33,34,39,51,53]. Ethnicity or race was considered
in only one study from this region in which prevalence
was reported separately for Maltese-born (16.7/100,000)
and foreign-born Maltese (166/100,000) residents [15].The British Isles
Together with the Italian peninsula, the British Isles was
the most studied region with 28 unique prevalence or in-
cidence studies. Of these, 13 were from England [57-69],
six from Scotland [21,70-74], three from Wales [75-77],
three from Northern Ireland [78-80], one from the Repub-
lic of Ireland [81], and one from the Channel Islands [82].
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the UK [83]. Allison and Millar criteria [3] were used,
either alone or in combination with Poser criteria, in
12/28 studies from this region conducted between 1985
and 1996 [61,63-65,67,68,70,72,77,79,80,82].
Prevalence estimates in the British Isles ranged from
96/100,000 in Guernsey [82] to more than 200/100,000,
with the highest estimates originating from Scotland
[21] and Northern Ireland [78]. These two countries also
had the highest annual incidence rates (7.2 to 12.2 per
100,000) [21,78].
Sequential studies of either the same or overlapping
populations in the South Glamorgan area of South Wales
[75-77], North-Eastern Northern Ireland [78-80], and the
Leeds health authority area in England [58,59] all demon-
strated increasing prevalence and incidence. For example,
in North-Eastern Northern Ireland the prevalence of
MS increased from 138/100,000 in the mid-1980s [79]
to 200.5/100,000 in 2004 [78].
Annual incidence sex ratios ranged from 1.24:1 in
North-Eastern Northern Ireland [78] to 2.82:1 in South-East
Wales [76]. The quality scores for studies from the British
Isles ranged from 2/7 to 8/8 with seven (25%) of the 28
studies [60,67,71,72,78,81,83] scoring 6 or higher. None of
the studies from the British Isles reported prevalence or inci-
dence by ethnic or racial subgroups.The Nordic region
Twenty-five studies were reviewed from the Nordic region,
including nine from Norway [17,84-91], five from Sweden
[18,92-95], four from Denmark [96-99], three from Finland
[19,22,100], three from Iceland [101-103] and one from
the Faroe Islands [104]. Most (19/25) of the studies used
the Poser diagnostic criteria alone or in combination
with other criteria. Four studies relied solely on McAlpine
[90,91,104] or Schumacher [18] criteria. Administrative
International Classification of Diseases (ICD) codes were
used to identify MS cases in two serial studies of the
Danish National Hospital Register [97,98].
The highest prevalence estimates in the Nordic region
(over 200/100,000) were reported in Seinajoki-South,
Finland [19] and in a small Northern rural district of
Sweden (population denominator 4,744) [18]. Familial
factors were suspected to play a role in the high number
of cases found in both populations according to the study
authors. The lowest prevalence estimates (20 - 30/
100,000) in the Nordic countries were documented in
Sami, Asian and African ethnic minority groups in Norway,
well below the prevalence among ‘Western’ Norwegians
(170/100,000) during the same time period [17,89]. Preva-
lence estimates were 150/100,000 or greater in the more
recently conducted studies from Norway, Denmark and
Sweden [17,85,88,95-98].Some of the highest annual incidence estimates in the
Nordic countries (9.2 and 11.6/100,000) were found in
specific central and Western regions of Finland [22,100].
A particularly low incidence was reported for the 1996-
2000 time period in Iceland (1.28/100,000) [103]. This
may be an underestimate however as it was based on the
incidence of MS symptom onset rather than year of
diagnosis; additional cases with onset during this period
may have been diagnosed after the findings were published
in 2002. Annual incidence estimates in Iceland from
the 1980s from the same study [103], as well as from a
separate earlier study [101], both reported rates similar to
that in other Nordic countries (4.1 - 5.3/100,000).
For the 11 studies that reported sex specific incidence
or incidence sex ratios, female to male annual incidence
ratios ranged between 1.2 and 2.2 with no major regional
or temporal differences. Quality scores ranged from 4/7 to
8/8, and seven (28%) of the studies, including all Danish
studies, scored 6/7 or higher [86,88,96-99,104]. MS preva-
lence in ethnic minority groups was investigated in the
two Norwegian studies described above [17,89].
Iberian Peninsula
One study from central Portugal [105] and 15 from
Spain were included in the review. The Spanish studies
included 11 conducted on the mainland [14,106-115],
three from the Canary Islands [12,116,117] and one from
the island of Menorca [118]. No studies incorporated
the entire country of either Spain or Portugal.
The lowest prevalence estimates originated from the
two earliest studies, conducted in the 1980s; from the
island of Lanzarote in the Canary Islands (15/100,000)
[12] and from the city of Valencia, Spain (17.7/100,0000)
[14]. Prevalence increased over time with the highest es-
timates (72 and 77/100,000) observed in the most recent
studies [106,112].
Ten studies from Spain studied annual incidence,
reporting values ranging from 2.2 to 5.3/100,000
[14,106,107,111-113,115-118] with the highest esti-
mates from studies concluded after 2000 [106,112,116].
Only two studies reported sex-specific incidence
figures. The female to male ratio was 1.73:1 in Menorca
[118] and 3.1:1 in Las Palmas City, Gran Canaria [116].
Quality scores ranged from 3/7 to 6/7 with three of the
15 studies (19%) scoring 6/7 [105,107,112]. One study
from this region estimated the prevalence of MS in the
minority Roma population in Malaga, Southern Spain
in 2002 as 52.9/100,000 [109], which was comparable
to estimates in the non-Roma population in the same
area in 1991 (53/100,000) [110].
Belgium and France
One prevalence study originated from Belgium [119] and
four incidence and/or prevalence studies were from France
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database to report national estimates [123].
Prevalence estimates ranged from 80-90/100,000, as
observed in Flanders, Belgium [119] and in mostly
Southern regions of France [123], up to 120-149/100,000
(2004) across regions of North-East France [123] and
including one crude estimate from the Haute-Garonne
region in South West France [122]. The overall prevalence
of MS in France was estimated at 94.7/100,000 [123].
The lowest reported annual incidence in this region
was from the city of Dijon in the mid-1990s (4.3/
100,000) [121]. Figures a decade later were higher; 7.5/
100,000 for the whole country with regional estimates
ranging from 6.1 to 10.8 [123].
Annual incidence sex ratios across France in 2004
demonstrated considerable variation; ranging from 1.4/
100,000 in Corsica to 4.1/100,000 in central France [123].
The quality scores for these studies varied between 5/7
and 7/8 with two of the studies (40%) scoring 7/8
[122,123]. No studies examined ethnic sub-groups in
either Belgium or France.
Central European countries
Six studies from Central Europe met selection criteria;
one from Switzerland [124], two from Germany [125,126],
one from Austria [127] and two from Hungary [128,129].
Crude prevalence estimates from this region ranged from
62/100,000 to 128/100,000. The lowest estimates origi-
nated from Hungary in the 1990s [128,129] and from
Germany in 1986 [125] while the highest estimate, also
from Germany, was found in the most recent study (2006)
[126]. Annual incidence was estimated in the studies from
Hungary and Germany to range between 6/100,000
and 7.7/100,000 without any clear temporal differences
[125,126,128,129].
Two studies provided female to male incidence ratios;
a ratio of 3:1 was reported in Germany in 2006 [126]
while an earlier study from Hungary completed in 1996
reported a ratio of 1.5:1 [129]. Quality scores in the Central
European studies ranged from 1/7 to 6/7 with only one
study (17%) scoring 6/7 [126]. No studies from this
region reported prevalence or incidence by ethnic or
racial subgroups.
South East Europe
Fourteen of the studies included in this review were
from South East Europe, covering the former Yugoslavia
[130,131], Croatia [132-134], Slovenia [134], Bosnia and
Herzegovina [135,136], Bulgaria [16,137], Romania [11],
Greece [138,139], and Greek- and Turkish-speaking com-
munities in Cyprus [23,24].
Most of the prevalence estimates in South East Europe
fell between a lower value of approximately 20/100,000,
as recorded in Romania [11] and in both rural and urbanRoma populations in Bulgaria [16], and an upper value
of approximately 50/100,000 in other regional studies
[23,24,131,133,135-137,139]. However, higher prevalence
estimates (144 and 152/100,000), were documented in
the Gorski Kotar region of North-West Croatia [130,134]
and in the neighboring region (the municipalities of
Kocevje and Ribnica) in South East Slovenia [134]. The
one-year incidence estimate for 1986 was also moderately
high (3.78/100,000) in these two regions, prompting
suspicion that a strong familial influence is at play in
this isolated population [130]. A study in western Greece
also reported high prevalence (120/100,000) and incidence
(9.5/100,000) estimates [138], that were notably higher
than those of a study conducted seven years earlier in the
northeastern region of Evros (prevalence of 38.9/100,000
and annual incidence of 2.36/100,000) [139]; possibly
explained by increased awareness, knowledge and avail-
ability of MRI machines [138]. Among the remaining
four studies that measured annual incidence of MS, es-
timates ranged from 0.32/100,000 in Romania [11] and
0.8/100,000 in Croatia [132] to 1.1 or 1.6/100,000 in re-
cent studies from Bosnia and Herzegovina [135,136].
One incidence study provided sex-specific data and
reported a female to male ratio of 1.69:1 in Western
Greece [138]. Quality scores in South East Europe range
from 2/8 to 6/7; only the two studies from Greece
[138,139] scoring 6/7. Ethnic differences were highlighted
by a 1998 report of MS prevalence among the Roma and
non-Roma population in two regions of Bulgaria. The
prevalence in the Roma (19/100,000) was found to be half
that of the non-Roma (45/100,000) population in both
regions [16].The Baltic states
Only one study from the Baltic States, a prevalence
study in Southern Estonia in 1989, was included [140].
Schumacher criteria were used to identify cases, and the
estimated prevalence in the entire population was 50/
100,000. The quality score for this study was 4/7. The
prevalence of MS in native Estonians was 55/100,000 in
contrast to 29/100,000 among those of Russian descent,
including those born in Estonia and first-generation
Russian immigrants.Discussion
This systematic review has comprehensively catalogued
the incidence and prevalence of MS across Europe be-
tween January 1985 and January 2011, and unlike prior
systematic reviews [141-143] of this region, has summa-
rized methodologies and evaluated study quality using
an objective measure and a predetermined set of criteria.
We aimed to describe potential temporal and demogra-
phic patterns that could be appreciated at the continental
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gions or populations that are under-represented.
Some European regions have undergone several MS
incidence or prevalence studies over this 27 year period;
more than 25 studies originated from each of the British
Isles, Italy, and the Nordic region. Spain has also been well
represented. Variability in representation within individual
countries was marked; of the 28 Italian studies, for ex-
ample, 16 were performed in either Sardinia or Sicily,
and only 12 on the mainland where most of the Italian
population lives. There is a relative paucity of studies
from Central and Eastern Europe and the 11 Sicilian
studies equal the total number of studies undertaken in
all of France, Belgium, Germany, Switzerland, Austria
and Hungary combined.
While much of the literature has focused on specific
regions or individual cities within a given country, a few
studies reported countrywide data [15,55,83,96-99,101,
103,123,127]. The extensive population of many European
countries limits the capacity to ascertain MS cases at the
national level. Administrative databases offer the means to
estimate the burden of MS at this level, but comparability
between studies has been limited due to the various case
definitions that have been used. These have included the
granting of permanent disability status with MS or the
need for disease modifying therapy [123], the presence of
an incident International Classification of Disease code
(ICD) for MS [97,98], and the more typical neurologist
confirmed diagnosis by standard criteria [83,96]. As vali-
dated case definitions for MS in administrative data are
now available [144,145], there is the potential for
greater comparability between estimates derived from
these sources in the future.
Ethnic differences were presented in very few reports.
Two Norwegian studies assessed MS rates in Asian
and African minority groups, or in the indigenous
Sami, separately from the remainder of the Norwegian
population [17,89], and found up to an eight-fold lower
prevalence in those groups. Non-Maltese born resi-
dents (mostly originating from Northern Europe) had
a 10-times higher prevalence than Maltese-born indi-
viduals [15]. Single studies from Spain [109] and
Bulgaria [16] revealed that prevalence was lower in the
Roma compared to non-Roma populations from the
same regions. Lastly, the Estonian report [140] exam-
ined Estonian- and Russian-born populations separ-
ately and found a lower prevalence in those originating
from Russia. Studies such as these provide unique and
valuable information, and can potentially be used to
differentiate the role of genetic and environmental fac-
tors in MS.
Prevalence and incidence estimates tended to be higher
in the Northern regions of the United Kingdom and in
the Nordic Countries, implicating the role of latitude. Thispattern is not uniform however, with higher estimates
originating as far south as Sicily and Greece [20,31,138].
Although there were some rare reports of lower preva-
lence ratios of women to men [18,23], the incidence
sex ratios (when available) revealed consistently higher
rates of women than men with MS across Europe with
no obvious patterns between north and south. The
issues of latitude-dependent gradients in MS incidence,
prevalence, and sex ratios, have been addressed in detail
by recent reviews [4,146].
The assessed quality of these epidemiological studies
varied both geographically and temporally. The more
recent literature had higher quality scores in general,
with the mean scores increasing from 4.31 for studies
with data collection before 1990, to 5.35 in those
conducted since 2000. The studies from France and
Belgium scored high on average; however, these were
also among the most recent. Those originating from
the British Isles were methodologically weaker overall
but included a greater proportion of earlier studies. When
comparing estimates between regions it is important to
recognize the inter-related issues of the methodological
quality of the study, the size of the source population, the
time period over which the study was performed and the
diagnostic criteria that were used. For example, the Poser
criteria were the most widely used (either alone or com-
bined with other criteria in 100 of the 123 studies), al-
though studies varied regarding inclusion of “probable”
and “possible” cases. However, many of the earlier studies
from the British Isles relied on the Allison-Millar or Rose
criteria; older criteria that may be more inclusive and
thereby might inflate prevalence or incidence estimates
[69,72]. However, any such effect depends on whether
cases in Allison-Millar’s “possible” or “early” categories
are included [72,77,80]. The definition of incidence also
varied, with most studies reporting incidence based on
the date of diagnosis, but others using the date of MS
symptom onset [15,39,40,42,46,55,70,87,101,103,117,118].
This latter definition can sometimes result in an apparent
decrease in incidence rates during the most recent time
period [103] due to the time-lag between onset and diag-
nosis [147-149].
The more recent studies reported higher MS preva-
lence or incidence estimates. Prevalence estimates would
be expected to increase over time if life expectancy of
those with MS increases; incidence is therefore considered
a better indicator of changes in disease rates [4]. However,
given the differences in study methodology and quality as
described above, it is difficult to determine if the observed
changes in incidence estimates over time are due to real
changes in the risk of MS. Additional factors which can
be related to an earlier diagnosis, including access to
neurological care and disease modifying therapies as
well as the availability of MRI, have also changed over
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appropriate standardization; only 42% of the prevalence
studies and 22% of the incidence studies included age-
and sex-standardized estimates, and among these, a variety
of standard populations were used. The effects of several
of these limitations have previously been highlighted and
recommendations have been made that would allow for
reliable comparisons between MS epidemiological studies
[142,143,150].
This review has some limitations. Once the data abstrac-
tion of the 123 unique studies from Europe was complete,
considerable inter-study variability was evident, preventing
a meaningful quantitative synthesis of the data even within
regions or countries. The included studies are limited
to publications in English or French and, although few
studies identified in the initial review were excluded
dues to language, their exclusion is likely to have biased
data collection in favour of Western European countries.
Of the 33 articles excluded for language, 13 originated
from countries not represented in this review; i.e. Russia,
the Ukraine, Poland and the Czech Republic or Slovakia.
The grouping of countries into eight European regions
was predominantly based on geography for descriptive
purposes, and these groupings may not be appropriate
for all questions related to the distribution of MS within
Europe. Strengths of the study included the comprehen-
sive assessment of study quality, and the independent data
abstraction by two reviewers with subsequent verification
by the first author and the comprehensive assessment
of study quality. This quality scoring system not only
offers a grading system for existing literature but a guide
to improving the design of future MS incidence and preva-
lence studies.
Conclusion
While there was marked variability in the methodological
quality of the studies reviewed, we can report that me-
thods seem to have improved over time, as demonstrated
by the trend towards higher quality scores in later studies.
Most prevalence and incidence estimates are derived from
towns or regions within a country, but national studies
have become increasingly feasible with the availability of
large databases and registries. The use of such resources
may improve comparability between estimates, although
attention should be paid to the validity and comparability
of case definitions. Spatial and temporal comparisons
would be facilitated if studies were to adopt a universal
standard population, and if age- and sex-specific estimates
were uniformly provided. The prevalence and incidence of
MS are not well documented in many regions of Europe.
As incidence and prevalence of MS vary considerably
between different ethnic populations, greater attention
should also be paid to the ethnic composition of source
populations and cases.Additional files
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